An Msh2 point mutation uncouples DNA mismatch repair and apoptosis

被引:151
作者
Lin, DP
Wang, YX
Scherer, SJ
Clark, AB
Yang, K
Avdievich, E
Jin, B
Werling, U
Parris, T
Kurihara, N
Umar, A
Kucherlapati, R
Lipkin, M
Kunkel, TA
Edelmann, W
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA
[2] NIEHS, Mol Genet Lab, Dept Hlth & Human Serv, NIH, Res Triangle Pk, NC 27709 USA
[3] Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA
[4] Harvard Partners Ctr Genet & Genom, Boston, MA USA
关键词
D O I
10.1158/0008-5472.CAN-03-2957
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations in the human DNA mismatch repair gene MSH2 are associated with hereditary nonpolyposis colorectal cancer as well as a significant proportion of sporadic colorectal cancer. The inactivation of MSH2 results in the accumulation of somatic mutations in the genome of tumor cells and resistance to the genotoxic effects of a variety of chemotherapeutic agents. Here we show that the DNA repair and DNA damage-induced apoptosis functions of Msh2 can be uncoupled using mice that carry the G674A missense mutation in the conserved ATPase domain. As a consequence, although Msh2(G674A) homozygous mutant mice are highly tumor prone, the onset of tumorigenesis is delayed as compared with Msh2-null mice. In addition, tumors that carry the mutant allele remain responsive to treatment with a chemotherapeutic agent Our results indicate that Msh2-mediated apoptosis is an important component of tumor suppression and that certain MSH2 missense mutations can cause mismatch repair deficiency while retaining the signaling functions that confer sensitivity to chemotherapeutic agents.
引用
收藏
页码:517 / 522
页数:6
相关论文
共 54 条
[1]  
Aebi S, 1996, CANCER RES, V56, P3087
[2]   Genetic and biochemical analysis of Msh2p-Msh6p: Role of ATP hydrolysis and Msh2p-Msh6p subunit interactions in mismatch base pair recognition [J].
Alani, E ;
Sokolsky, T ;
Studamire, B ;
Miret, JJ ;
Lahue, RS .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (05) :2436-2447
[3]   Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent [J].
Andrew, SE ;
McKinnon, M ;
Cheng, BS ;
Francis, A ;
Penney, J ;
Reitmair, AH ;
Mak, TW ;
Jirik, FR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (03) :1126-1130
[4]   The mismatch repair system is required for S-phase checkpoint activation [J].
Brown, KD ;
Rathi, A ;
Kamath, R ;
Beardsley, DI ;
Zhan, QM ;
Mannino, JL ;
Baskaran, R .
NATURE GENETICS, 2003, 33 (01) :80-84
[5]   Mammalian DNA mismatch repair [J].
Buermeyer, AB ;
Deschênes, SM ;
Baker, SM ;
Liskay, RM .
ANNUAL REVIEW OF GENETICS, 1999, 33 :533-564
[6]   1,2-dimethylhydrazine-induced colon carcinoma and lymphoma in msh2-/- mice [J].
Colussi, C ;
Fiumicino, S ;
Giuliani, A ;
Rosini, S ;
Musiani, P ;
Macrí, C ;
Potten, CS ;
Crescenzi, M ;
Bignami, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (20) :1534-1540
[7]   The mammalian mismatch repair pathway removes DNA 8-oxodGMP incorporated from the oxidized dNTP pool [J].
Colussi, C ;
Parlanti, E ;
Degan, P ;
Aquilina, G ;
Barnes, D ;
Macpherson, P ;
Karran, P ;
Crescenzi, M ;
Dogliotti, E ;
Bignami, M .
CURRENT BIOLOGY, 2002, 12 (11) :912-918
[8]   Involvement of the mismatch repair system in temozolomide-induced apoptosis [J].
D'Atri, S ;
Tentori, L ;
Lacal, PM ;
Graziani, G ;
Pagani, E ;
Benincasa, E ;
Zambruno, G ;
Bonmassar, E ;
Jiricny, J .
MOLECULAR PHARMACOLOGY, 1998, 54 (02) :334-341
[9]  
de Leeuw WJF, 2000, J PATHOL, V192, P328, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH701>3.0.CO
[10]  
2-2